Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.
Invasive disease due to Neisseria meningitidis continues to cause debility and death worldwide in otherwise healthy individuals. Disease epidemiology varies globally, but most cases are due to serogroups A, B, C, W-135 or Y. MenactraTM (MCV-4), a quadrivalent, meningococcal diphtheria-conjugate vaccine against serogroups A, C, Y, and W-135, was licensed in the USA for individuals 11-55 years of age. Published results of clinical trials demonstrated robust immune responses that correlate with indicators of protection. MCV-4-induced antibody persist for up to 3 years after administration and anamnestic responses to revaccination. The vaccine was well tolerated; the most common reactions were transient, mild injection-site reactions and headache. MCV-4 should provide significant clinical benefits in the future.
Keyserling
Harry L
HL
Emory University School of Medicine, 2015 Uppergate Drive, Atlanta, GA 30322, USA. hkeyser@emory.edu
Pollard
Andrew J
AJ
DeTora
Lisa M
LM
Gilmet
Gregory P
GP
D000907:Antibodies, Bacterial; D004168:Diphtheria Toxoid; D006801:Humans; D008581:Meningitis / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D022401:Meningococcal Vaccines; D012703:Serotyping; D018074:Vaccines, Conjugate / Q000009:adverse effects
D000907:Antibodies, Bacterial; D004168:Diphtheria Toxoid; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate